Pharmaceuticals & Biotech Businesses for Sale.

The compliance infrastructure, multi-year customer contracts, and switching costs built into regulated workflows are what make the best pharma and biotech businesses so hard for competitors to replicate.

Browse Listings
21
Active Listings
$2.3M
Median Asking Price
Browse listings

Featured Pharmaceuticals & Biotech Businesses

Showing 21 of 21 listings

Mushroom Wellness Products Business

Artisan mushroom extract manufacturer with proprietary extraction processes, 80-90% private label and contract manufacturing revenue, and over five years of consecutive revenue growth in the fast-expanding functional mushroom category.
Price$1.2M
Revenue$2.1M
SDE$335.9K

Vitamins / Supplements Business

Patented oral spray supplement brand using microemulsion technology for higher absorption, with revenue growing from $76.9k in 2022 to $221.9k in 2025 and projected at $450k in 2026.
Price$300K
Revenue$221.9K
SDE$41.6K

Chemical Supplier

A research biochemicals supplier specializing in small molecule drugs with over 50,000 listed products, an established overseas manufacturing network, and no FDA regulatory burden.
Price-
Revenue$3M
SDE$1M

Pain Management Medical Device Company

Healthcare technology manufacturer of non-narcotic, non-surgical pain management devices scaled from $1.5M to $4.8M in revenue over three years with 50% EBITDA margins.
Price$20M
Revenue$4.8M
SDE$2.4M

Custom Bioassay Research Solutions

Life sciences reagent and immunoassay business with proprietary monoclonal antibody IP, a GLP-compliant facility, and a tenured six-person team that runs operations independently of the owner.
Price$4.3M
Revenue$2.4M
SDE$802.3K

Pharma Digital Creative Agency

Digital creative agency producing science-based video content and differentiation strategies for pharmaceutical and biotech companies, generating revenue through contract and project-based engagements.
Price$300K
Revenue$150K
EBITDA$12.8K

Online Health and Wellness Store

Online vitamins and supplements retailer with over twenty years of operating history, direct US and Canadian manufacturer relationships, 10% subscription revenue, and automated multichannel fulfillment across major e-commerce marketplaces.
Price-
Revenue$900K
EBITDA($20K)

At-Home Allergy Immunotherapy Platform

Y Combinator-backed telehealth allergy platform with 97% recurring subscription revenue, $2.5M in annual sales, and a fully remote, SOP-driven care delivery model.
Price-
Revenue$2.5M
SDE$109.5K

Heath Information Publication Business

A health and wellness content platform with over forty years of brand equity, a 140,000-plus email subscriber base with 30-35% open rates, and diversified revenue across subscriptions, guides, advertising, and e-commerce.
Price-
Revenue$530.2K
SDE$7.4K

Wellness Products Retailer

Direct-to-consumer wellness supplement brand with an eleven-year Amazon storefront, 1,688 Subscribe & Save subscribers, and 75% SDE margins in 2025.
Price$2.3M
Revenue$514.5K
EBITDA$385.8K

Pharmacy

Full-service retail and non-sterile compounding pharmacy in Southern California generating $4M in revenue with $1.1M in SDE through personalized medication, wellness programs, and concierge delivery services.
Price-
Revenue$4M
SDE$1.1M

Biotech Drug Discovery Enzyme Supplier

Niche life sciences company with proprietary IP covering the full spectrum of human topoisomerases and DNA repair enzymes, three distinct revenue streams, a debt-free owned lab facility, and over 3,000 literature citations across more than twenty years of operations.
Price-
Revenue$246.1K
SDE$229.6K

Human Tissue Biotech Solutions

Patent-holding life sciences business providing human-derived tissue solutions for pre-clinical drug development, with $2.1M in 2025 revenue and tripled earnings year-over-year.
Price$10M
Revenue$2.1M
SDE$300K

Biotechnology Research Company

Biotechnology contract research organization providing drug development support across bioanalysis, biochemistry, molecular biology, and advanced cell engineering for biopharmaceutical companies.
Price$500K
Revenue$319.2K
SDE$112.3K

Spectrometry & Research Services Company

Mass spectrometry CRO serving biotech and pharma grew revenue from $1.1M in 2023 to $2.1M in 2025 through organic growth alone, with instruments running at only 50-70% utilization and zero dedicated sales staff.
Price$4M
Revenue$2.1M
SDE$516.2K

Regenerative Healthcare Business

Vertically integrated regenerative medicine platform spanning 80 clinics across eight countries, two proprietary labs, and a training division with 29,000 procedures completed and $15M revenue in 2025 growing toward $20M.
Price-
Revenue$15M
SDE$1.5M

Life Sciences Medical and Laboratory Supply

A 16-year government contract anchor and 213 active accounts have driven revenue from $1.6M in 2021 to over $4.1M in 2025, with a recently renewed five-year municipal contract providing a durable base for continued growth.
Price-
Revenue$4.1M
SDE$266.7K

Software Solutions Company for Pharmaceutical Industry

Two proprietary software products serve a global pharma niche with only one competitor worldwide, generating recurring subscription revenue from 25+ client sites across big pharma, biotech, and contract research organizations.
Price$740K
Revenue$325.5K
SDE$219.9K

Lab Testing and Consulting for Food and Drug Industry

Analytical testing laboratory serving cannabis, hemp, food, and pharmaceutical industries with $1.3M in revenue and $225k in EBITDA in 2024.
Price-
Revenue$1.3M
EBITDA$225K

Pharmaceutical Analytics Business

Pharmaceutical analytics platform with 75% margins, recurring subscription revenue, and a preferred partnership with a major EHR provider serving over 14,000 clients.
Price-
Revenue$250K
EBITDA$187.5K

Medical Weight Loss & Wellness Clinic

Physician-run medical weight loss practice with over fifty years of operating history, 100% cash-pay revenue, two locations in the Washington, D.C. metro area, and 49% revenue growth from 2024 to 2025 driven by GLP-1 program adoption.
Price$4M
Revenue$1.2M
EBITDA$221.7K
Explore with filters

Search, filter, and find your perfect opportunity

Due diligence

What to Look For

Practical guidance from hundreds of real acquisition conversations.

Subscription Revenue Share

  • Ask what percentage of revenue comes from subscriptions or annual contracts that renew automatically versus one-time project work.
  • High recurring revenue changes the risk profile from day one and tends to support stronger financing terms.
  • A business where 60 percent or more of revenue is contracted and predictable is a very different starting point than a project-driven one.

Customer Switching Costs

  • In regulated industries, switching away from a compliance or traceability platform requires a full revalidation process that can cost hundreds of thousands of dollars and months of disruption.
  • Ask how embedded the product is in each customer's actual operations, not just how long they've been a customer.
  • Customers who would need months to revalidate before switching are the kind of retention story that holds through ownership changes.

Customer Tenure and Concentration

  • Ask for a customer list with tenure dates, even if names are anonymized early in the process.
  • Customers on the platform for five or more years without churning are a strong signal that the product genuinely delivers what it promises.
  • Check whether any single customer represents more than 20 to 25 percent of revenue, and spend time understanding that relationship if they do.

Compliance Documentation

  • Ask to see FDA records, validation documentation, and compliance certifications, and check that they're organized and current.
  • Missing or disorganized compliance records can slow the process down and create questions that are hard to answer quickly.
  • A seller with clean, well-maintained compliance files is signaling that the business has been run with real discipline.

Expansion Potential

  • Some of the best businesses in this space have proven their platform in one vertical and have clear, untapped potential in adjacent ones like animal health, food safety, or medical devices.
  • Ask where the product has already expanded and where it hasn't yet, which tells you a lot about the growth opportunity you'd be acquiring.
  • A proven platform in one regulated market with a natural path into a second is a meaningful strategic advantage.

Valuation

What Should You Expect to Pay?

3x-6x

SDE

Founder-dependent with some recurring revenue

6x-12x

EBITDA

With team running independently and high recurring revenue from long-tenure customers

The spread is driven by how much revenue is truly recurring, how embedded the product is in customer operations, and whether the business can run without the founder's direct involvement.

What drives a premium

Majority of revenue from annual subscriptions that renew without active sales effort

Customers deeply embedded in the platform with high switching costs due to revalidation requirements

Multi-year customer retention with documented tenure history across the customer base

Compliance records including FDA documentation and validation certifications organized and current

SBA Loan Calculator

See what your monthly payments would look like at different deal sizes

Thinking About Selling?Read our owner's guide to selling a pharmaceuticals & biotech business, with valuation tips, buyer expectations, and step-by-step advice.
Read the Owner's Guide

Pharmaceuticals & Biotech Business Acquisition

Start with the revenue model. Businesses where most revenue comes from subscriptions that renew automatically are fundamentally more predictable than those dependent on new customer acquisition. Then understand customer switching costs. In regulated industries, embedded compliance and traceability tools are very hard to replace, which keeps customers in place. Browse pharmaceuticals and biotech businesses for sale on Rejigg to see what's currently available.
Most pharma and biotech businesses sell for 3 to 12 times annual profit, with the wide range reflecting the significant difference between founder-dependent services businesses and highly recurring software platforms with strong customer retention. Use the SBA loan calculator to model your financing options and required equity.
Ask for a breakdown of recurring versus non-recurring revenue. Get customer tenure data and understand the concentration of your top five customers. Review compliance documentation including FDA records and validation certificates. Understand whether any key technical or regulatory knowledge is concentrated in the founder, and ask how the team is structured to handle customer relationships independently.
Ask what percentage of revenue comes from subscriptions that renew without active sales effort. Find out how long each of the top customers has been active and whether any have contracted for multi-year terms. Ask to see FDA documentation and validation records. Understand the technical architecture and whether switching away from the platform requires revalidation. Ask about the founder's involvement in customer relationships and the transition plan.
Rejigg connects buyers with owners of pharma software companies, biotech services businesses, compliance platforms, and other regulated life sciences companies. You can browse pharmaceuticals and biotech businesses for sale on Rejigg and connect with owners directly.
Regulation is actually a positive factor when it comes to customer retention. Compliance and traceability requirements create steady demand for products and services that help manufacturers meet those requirements. Once a company is set up and validated on a system, switching to a competitor involves a costly revalidation process. That dynamic creates durable customer loyalty that buyers find genuinely valuable.
Founder-dependent customer relationships are one of the most common risk factors in this space and worth understanding clearly. Ask whether the technical team and account managers have their own direct relationships with customers, and how long those have been in place. A thoughtful transition plan where the seller stays involved for a defined period can bridge this gap effectively, but you want to understand the landscape before you close.